病例討論~張琮琨、王照元-使用regorafenib合併FOLFIRI與UGT1A1基因檢測治療轉移性直腸癌臨床病例報告

1. ( 5FU/
LV, oxaliplantin, irrinotecan )
( anti-VEGF monoclonal antibody,
anti-EGFR monoclonal antibody)
regorafenib
VEGFR-1,
-3 RAF BRAF
regorafenib
28 21
160mg
regorafenib
regorafenib FOLFIRI
73 100 4
(pT3N1M0)
FOLFOX
101 9
101 10 102 5
FOLFIRI
capecitabine 102 5 103
5 5

2. 103 11
104 9 FOLFIRI
Bevacizumab 12
105 6 FOLFIRI
regorafenib
29 29
regorafenib
CORRECT CONCUR
regorafenib
(overall
survival) 23 45%
(progression free
survival) 51 69%
regorafenib (disease
control rate) 41 51.5%
Schmieder
regorafenib irinotecan
regorafenib
irinotecan
Schultheis
regorafenib FOLFIRI
regorafenib FOLFOX
regorafenib
FOLFIRI
UGT1A1 irinotecan
regorafenib
UGT1A1
TA6/TA6 TA6/TA7 irinotecan
180 mg/m2

3. 30 mg/m2
260 mg/m2
TA7/TA7
120 mg/m2
30 mg/m2
180 mg/m2
regorafenib
28
120 mg
Irinotecan
( )
regorafenib
(hand-foot skin reaction)
regorafenib FOLFIRI
29
regorafenib
regorafenib FOLFIRI
UGT1A1